Wound Care Research

Wound Care.

It is staggering to think that 200,000 patients in the UK suffer from chronic wounds.

REF. J Posnett et al., Nursing Times, 2008.

 

 

 

http://www.nursingtimes.net/nursing-practice/specialisms/wound-care/the-burden-of-chronic-wounds-in-the-uk/527138.article.

This is a terrible burden for the patients, and a massive financial burden on the NHS.

The total cost of treating the least severe type of chronic wound, a grade 1 pressure ulcer, starts at around £1,000. For the most severe types, the overall treatment cost can be >£20,000.

 

http://www.nhs.uk/Conditions/Pressure-ulcers/Pages/Symptoms.aspx

The total cost for managing wounds in the UK has been estimated at £2 – 3 billion p.a., approximately 4% of the NHS budget.

 

Wound Care Research at Mologic.

Mologic has a long history in developing assays for the detection of proteases, specifically those involved during the inflammatory process. In our inimitable way we later further developed these for use in lateral flow devices.
These are cheap to make, simple to use and highly suited for point of care use.

In 2008 our “ELTABA’ Technology was patented for the detection of protease activity in wound fluid.

Chemicals Produced by Neutrophil Leucocytes.

Neutrophil leukocytes have many damaging biochemical agents, which they release into the tissues where they are fighting microbes.  We are focussing on one group in particular, called proteases including matrix metalloproteases MMPs and human neutrophil elastase (HNE).

Damaging Biochemical Agents produced by Neutrophil Leucocytes.

WoundDiagram

Wounds are slower to heal if the levels of protease enzymes, particularly MMPs and Human Neutrophil Elastase, are high. Diagnostics capable of identifying these wounds enable the selection of the most suitable course of treatment for the patient.

When Mologic was part of the Alere group of companies, we developed a diagnostic looking at elevated protease markers.

This product was the world’s first wound diagnostic, bought to market by the diagnostic division of Systagenix (Now WOUNDCHEK Laboratories), marketed as Woundchek.

 

Mologic has continued to develop and improve this concept for the detection of protease levels and other markers of wound infection. A range of positive read diagnostic assays are available and already in our product development pipeline.

Combining diagnostic research with assay development has given our world-class team the edge: our expertise in assay development is growing and developing fast.

We’re attracting interest from industrial partners as well as some very exciting grant-funded activities.

As you can see, Mologic have been leading the way
in the wound research game for many years.

Mologic presented their wound research at
The European Tissue Repair Society
and the Union of World Healing Conferences in 2008..
Click on image to view our poster.
WoundPosterPicture

 

Working Group Review.
Click on image to view.
ExpertWorkingGroupImage

Round-Table Meeting.
Click on image to view.
RoundTableImage

Lab statistics

image for Visitors Greeted
Visitors Greeted

212

in the last month

image for Problems solved
Problems solved

79

this year

image for Peptides synthesised
Peptides synthesised

10

this year to-date

image for Hours in the lab
Hours in the lab

67500

so far this year

EXPLORE WHAT WE CAN DO AT MOLOGIC

Take a look at our expertise. And if you can't see exactly what you're after, contact us. We'll be delighted to discuss your project with you.

Contact us